Apriori: Variant-proofing vaccines and antibodies

As the newest company to emerge from Flagship Pioneering, Apriori aims to end the viral variant chasing that has prevented vaccine and therapeutic developers from keeping pace with evolving pathogenic threats — including SARS-CoV-2.

Apriori Bio Inc., which was launched by Flagship in 2020 with $50 million, has an AI-driven platform named Octavia designed to help create variant-proof preventive countermeasures for rapidly evolving viruses...